US Stock and Financial News

Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion

Acquiring the maker of a recently approved drug for sickle-cell disease would be the latest move by the drug giant to bolster its portfolio and pipeline.

Related Articles

Back to top button